5 news items
Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
THTX
23 May 24
the Company's control, that could cause actual results to differ materially from those that are disclosed in or implied by such Forward-Looking Statements
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
THTX
2 May 24
of which are beyond the Company's control, that could cause actual results to differ materially from those that are disclosed in or implied by such Forward
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
THTX
10 Apr 24
of the Interim Financial Statements). As of February 29, 2024, the material covenants of the credit agreement providing for the Loan
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technologyâ„¢ Oncology Platform
THTX
8 Apr 24
are subject to a number of risks and uncertainties, many of which are beyond the Company's control, that could cause actual results to differ materially
Theratechnologies Appoints Elina Tea to its Board of Directors
THTX
5 Apr 24
and uncertainties, many of which are beyond Theratechnologies' control that could cause actual results to differ materially from those that are disclosed
- Prev
- 1
- Next